| Upcoming events on ELI LILLY AND COMPANY |
|
| 01/29/21 | | Esercizio 2020 Pubblicazione dei risultati |
| 01/29/21 | 03:00pm | | Esercizio 2020 Presentazione dei risultati |
| 02/11/21 | | Desprendimiento de dividendo |
| 04/27/21 | 03:00pm | | Q1 2021 Presentazione dei risultati |
|
| Past events on ELI LILLY AND COMPANY |
|
| 01/12/21 | 02:20pm | | JP Morgan Healthcare Conference |
| 12/15/20 | 02:30pm | | Esercizio 2021 Previsioni della società |
| 12/09/20 | | San Antonio Breast Cancer Symposium |
| 12/01/20 | 08:40pm | | Evercore ISI HealthCONx Conference |
|
| Upcoming sector events for ELI LILLY AND COMPANY |
|
|
| |
|
| Past sector events for ELI LILLY AND COMPANY |
|
|
|
|
|
| Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales
M $ |
Released
Forecast
Spread | 19 959
19 904
0,27% | 21 222
20 992
1,1% | 22 871
22 638
1,0% | 24 556
24 404
0,62% | 22 320
22 142
0,80% |
24 415
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 5 799
5 617
3,2% | 5 368
5 549
-3,3% | 6 541
6 474
1,0% | 7 829
7 943
-1,4% | 7 551
7 508
0,57% |
8 713
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 4 371
4 448
-1,7% | 4 555
4 668
-2,4% | 5 649
5 617
0,57% | 6 766
6 743
0,34% | 6 079
6 106
-0,44% |
7 529
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 2 790
3 431
-19% | 3 374
3 647
-7,5% | 2 197
2 230
-1,5% | 3 796
3 930
-3,4% | 5 266
8 975
-41% |
7 041
|
Net income
M $ |
Released
Forecast
Spread | 2 408
2 632
-8,5% | 2 738
2 806
-2,5% | -204
1 756
-112% | 3 232
3 281
-1,5% | 8 318
8 090
2,8% |
5 821
|
EPS
$ |
Released
Forecast
Spread | 2,26
2,44
-7,2% | 2,58
2,63
-1,9% | -0,19
1,65
-111% | 3,13
3,14
-0,18% | 8,89
8,65
2,8% |
6,38
| | Announcement Date | 01/28/2016 | 01/31/2017 | 01/31/2018 | 02/06/2019 | 01/30/2020 | |
|
|
|
| Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales
M $ |
Released
Forecast
Spread | 6 355
6 050
5,0% | 6 062
6 044
0,30% | 6 439
6 280
2,5% | 5 092
5 116
-0,46% | 5 637
5 589
0,85% | 5 477
5 496
-0,35% | 6 114
5 923
3,2% | 5 860
5 481
6,9% | 5 499
5 769
-4,7% | 5 741
5 867
-2,1% |
7 270
|
6 670
|
6 789
|
6 700
|
7 232
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 2 125
1 909
11% |
| 1 875
| 1 691
1 713
-1,3% |
|
|
| 2 036
2 024
0,58% | 1 865
2 100
-11% | 1 865
2 539
-27% |
3 221
|
|
|
|
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 1 852
1 617
15% | 1 692
1 657
2,1% | 1 617
1 613
0,23% | 1 334
1 486
-10% | 1 575
1 631
-3,5% | 1 565
1 590
-1,6% | 1 605
1 694
-5,2% | 1 762
1 598
10% | 1 541
1 764
-13% | 1 506
1 832
-18% |
2 588
|
2 005
|
2 152
|
2 212
|
2 468
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 4,80
1 460
-100% | 1 411
1 478
-4,5% | 939
| 731
1 140
-36% |
|
|
|
|
|
|
|
|
|
|
|
Net income
M $ |
Released
Forecast
Spread | -260
947
-127% | 1 150
1 207
-4,8% | 1 125
1 215
-7,4% | 4 242
906
368% | 1 327
1 306
1,7% | 1 254
1 273
-1,5% | 1 496
1 456
2,7% | 1 457
1 206
21% | 1 412
1 395
1,2% | 1 208
1 447
-17% |
1 995
|
|
|
|
|
EPS
$ |
Released
Forecast
Spread | -0,25
0,90
-128% | 1,12
1,17
-4,3% | 1,10
1,19
-7,2% | 4,31
0,95
354% | 1,44
1,41
2,1% | 1,37
1,38
-0,76% | 1,64
1,54
6,3% | 1,60
1,35
18% | 1,55
1,53
1,6% | 1,33
1,61
-18% |
2,06
|
|
|
|
| | Announcement Date | 07/24/2018 | 11/06/2018 | 02/06/2019 | 04/30/2019 | 07/30/2019 | 10/23/2019 | 01/30/2020 | 04/23/2020 | 07/30/2020 | 10/27/2020 | | | | | |
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
|
Eli Lilly to buy gene therapy developer Prevail in about $1 bln deal |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
Previous period
